Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody− calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann, LM Hinman, I Hollander… - Bioconjugate …, 2002 - ACS Publications
CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin
AD Ricart - Clinical Cancer Research, 2011 - AACR
Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …
An anti-CD33 antibody− calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
PR Hamann, LM Hinman, CF Beyer, D Lindh… - Bioconjugate …, 2002 - ACS Publications
The anti-CD33 antibody, P67. 6, has been chosen to target the potently cytotoxic
calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the presence of …
calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the presence of …
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph, DC Armellino, ER Boghaert, K Khandke… - Blood, 2004 - ashpublications.org
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted
immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent …
immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent …
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
PF Bross, J Beitz, G Chen, XH Chen, E Duffy… - Clinical cancer …, 2001 - AACR
Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic …
VHJ van der Velden, JG te Marvelde… - Blood, The Journal …, 2001 - ashpublications.org
Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid
leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which …
leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which …
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
S Lapusan, MB Vidriales, X Thomas, S De Botton… - Investigational new …, 2012 - Springer
The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
Gemtuzumab ozogamicin for acute myeloid leukemia
FR Appelbaum, ID Bernstein - Blood, The Journal of the …, 2017 - ashpublications.org
Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
Pharmacokinetics of gemtuzumab ozogamicin, an antibody‐targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell, J Korth‐Bradley, H Liu… - The Journal of …, 2001 - Wiley Online Library
The purpose of this study was to characterize the pharmacokinetics of gemtuzumab
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of
the humanized murine CD33 antibody (clone P67. 6) to which the calicheamicin-g1 …
the humanized murine CD33 antibody (clone P67. 6) to which the calicheamicin-g1 …
相关搜索
- myeloid cells cd33 calicheamicin
- gemtuzumab ozogamicin leukemia patients
- gemtuzumab ozogamicin antibody drug
- gemtuzumab ozogamicin treatment of adults
- choice of linker calicheamicin conjugate
- gemtuzumab ozogamicin chemotherapy agent
- gemtuzumab ozogamicin fda approval
- gemtuzumab ozogamicin treatment of patients
- inotuzumab ozogamicin antibody drug